Victoria Socha

DocwireNews

According to researchers in Germany, polyuria induced by V2R-antagonists has caused concern regarding the tolerability of tolvaptan in the real-life setting. Questions regarding tolerability include how patients cope with increased urine volume, what is the sufficient adherence level to reach the desired effect, and how does the medication affect patients&rsquo; quality of life.The researchers, led by Mussa Keaei, MSc, conducted the AD(H)PKD study, collecting data from patients with autosomal dominant polycystic kidney disease (ADPKD) presenting with the question whether they should take tolvaptan on a yearly basis. Results of the study were reported during a poster session at Kidney Week 2019 in a poster titled Using Tolvaptan for ADPKD: Feasibility and Patient-Reported Outcome in the Real-Life Setting.One aspect of the study was a self-developed questionnaires to identify patient-reported outcomes, with particular focus on complications and adherence. Quality of life and pain measurements were ascertained using the 12 item Short Form (SF-12) Health Survey and a translated version of the HALT-PKD (Halt Progression of Polycystic Kidney Disease) study pain questionnaire.The study began in late 2015; since the start, more than 560 patients have been enrolled. In the majority of patients on tolvaptan, urine volume increases to 5 to 75 liters. The largest increase occurs when initiating the first dose step; further uptitration leads to only a minor change. Adherence to long-term tolvaptan therapy is approximately 80%; most patients who discontinue therapy with tolvaptan reported events associated with polyuria.The majority of patients in the study did not consider therapy with tolvaptan a major problem. However, approximately two-thirds report that a minor adaptation of everyday life was required. Approximately 65% reported that the increased urine volume presents a burden rarely; approximately 23% reported that the increases urine presents a burden often or always.More than 90% said they would recommend tolvaptan therapy to other patients.When asked about adherence, patients reported skipping a dose only rarely; leisure-time, professional, and medical reasons were cited as associated with skipping a dose. In the overall cohort, there was no difference in reported quality-of-life between patients with and without tolvaptan. There was also no difference longitudinally in patients prior to and following initiation of tolvaptan therapy.In conclusion, the researchers said, &ldquo;Our data indicate that taking tolvaptan&mdash;despite the increase in urine volume&mdash;is well feasible for most patients without major adaptations to everyday life. Around 20% consider the polyuria a significant burden and about the same percentage discontinued the therapy in the long term. Quality of life is not affected by polyuria and nearly all participants would tell others to try the therapy if recommended by their nephrologist. Taken together, our data will help to increase confidence of nephrologists in using tolvaptan for ADPKD and to guide patient counseling when starting the treatment.&rdquo;Source: Keaei M, Todorova P, Oehm S, et al. Using tolvaptan for ADPKD: Feasibility and patient-reported outcome in the real-life setting. Abstract of a poster presented at the American Society of Nephrology Kidney Week 2019 (Abstract TH-PO836), November 7, 2019, Washington, DC.

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Tolvaptan in Patients with ADPKD: Patient-Reported Outcomes

ADPKD

According to researchers in Germany, polyuria induced by V2R-antagonists has caused concern regarding the tolerability of tolvaptan in the real-life setting. Questions ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe